ADC Therapeutics SA

ADC Therapeutics SA

ADCTNYSE / NASDAQHealthcareSmall cap

$1.28-$0.02 (-1.5%)

Last close · Data as of Nov 20, 2026

Market cap
$167.9M
P/E
-1.2x
EV / EBITDA
-0.3x
Revenue
$81.4M
Net margin
-175.3%
ROCE
-42.4%

This period includes a one-day price step on 4 Jun 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

ADC Therapeutics SA price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-15.8%
3M
+33.3%
6M
Hidden
1Y
Hidden
5Y
Hidden
  • This period includes a one-day price step on 4 Jun 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

This period includes a one-day price step on 4 Jun 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Day change -$0.02 (-1.5%) from $1.30 to $1.28 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ADCT, bought on each weekday since 2021.

News & filings

What ADC Therapeutics SA filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • Cash on the balance sheet is more than the company's market value.
  • The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.
  • This period includes a one-day price step on 4 Jun 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States.

Read moreShow less

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Sector
Healthcare
Shares outstanding
125.8M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$167.9M
P/E
-1.2x
P/B
-0.9x
EV / EBITDA
-0.3x
EV / Sales
0.3x
P/S
2.1x
52-week high
Hidden
52-week low
Hidden

Profitability

Operating margin
-131.8%
Net margin
-175.3%
EBITDA margin
-108.3%
ROE
76.7%
ROCE
-42.4%
ROA
-44.1%
Asset turnover
0.25

Growth

Revenue
$81.4M
Revenue growth, 1Y
14.9%
Revenue CAGR, 3Y
-27.1%
Net profit growth, 1Y
-9.6%
Free cash flow
-$141.4M

Solvency

Current ratio
4.37
Debt / Equity
-0.63
Debt / Assets
0.36
CFO / Net profit
0.99
Cash / Market cap
155.7%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$81.4M
Cost of revenue$5.8M
Gross profit$75.6M
Operating expenses$182.8M
Research and development$104.0M
Selling, general and administrative$79.9M
Operating income-$107.2M
Interest and other-$34.4M
Pretax income-$141.6M
Tax and other$1.0M
Net income-$142.6M

Revenue and net profit

Revenue grew 14.9% in FY2025; net profit is the dashed line.

ADC Therapeutics SA revenue and net profit by fiscal year
ADC Therapeutics SA revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$209.9M-$157.1M
FY2023$69.6M-$240.1M
FY2024$70.8M-$157.8M
FY2025$81.4M-$142.6M

Cash flows

FY2025: -$141.2M from operations, -$141.4M free after investment (dashed).

ADC Therapeutics SA operating and free cash flow by fiscal year
ADC Therapeutics SA operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$138.3M-$139.0M
FY2023-$118.7M-$121.9M
FY2024-$123.8M-$124.7M
FY2025-$141.2M-$141.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$81.4M+14.9%1Y
EBITDA
-$88.1M
Net profit
-$142.6M
Cash from operations
-$141.2M
Free cash flow
-$141.4M
Revenue CAGR, 3Y
-27.1%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$81.4M-$88.1M-$142.6M-$141.4M76.7%+14.9%-9.6%

Monthly returns

Month-by-month returns of ADCT across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$323.1M
Liabilities$509.0M
Equity-$185.8M
Paid-in capital$1.4B
Retained earnings-$1.6B
Treasury stock$200.0k

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ADCT highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. ADC Therapeutics SA (this company)0.3x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
ADC Therapeutics SAADCTthis company$167.9M-1.2x-0.9x76.7%-0.3x
MediWound Ltd.MDWD$185.7M-7.8x4.3x-54.7%-8.8x
Stereotaxis, Inc.STXS$183.7M-8.5x13.6x-160.5%-8.5x
Quanterix CorporationQTRX$179.0M-1.7x0.6x-36.2%-2.1x
Journey Medical CorporationDERM$171.3M-15.0x5.4x-35.9%-51.9x
Inogen, Inc.INGN$170.8M-7.5x0.9x-11.8%-8.9x
Protalix BioTherapeutics, Inc.PLX$161.9M—3.4x-13.7%—
Korro Bio, Inc.KRRO$161.2M-1.4x3.1x-228.0%-2.2x
CVRx, Inc.CVRX$156.0M—4.0x-135.6%—
Peer median—-7.6x3.7x-45.5%-8.7x

Year-to-date ROI

ADCT since 1 January, against earlier years.

Historical volatility

ADCT's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

ADC Therapeutics SA operating margin by fiscal year
ADC Therapeutics SA operating margin by fiscal year
DateOperating margin
FY2022-58.6%
FY2023-237.3%
FY2024-182.9%
FY2025-131.8%
LineFY2025
Cost of revenueCost Of Revenue$5.8M
Gross profitGross Profit$75.6M
Operating expensesOperating Expense$182.8M
Research and developmentResearch And Development$104.0M
Total expensesTotal Expenses$188.6M
Pretax incomePretax Income-$141.6M

Learn while you research

Academy chapters picked for ADC Therapeutics SA and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →